Autologous hematopoietic stem cell transplant in a patient with leprosy: Is it safe?

Matias Chiarastelli Salomão; Marjorie Vieira Batista; Maria Cristina de Macedo; Mirian Nacagami Sotto; Amaro Nunes Duarte; Vanderson Geraldo Rocha; Hermes Ryoiti Higashino; Silvia Figueiredo Costa

doi:10.1111/tid.12840

Autologous hematopoietic stem cell transplant in a patient with leprosy: Is it safe?

Transpl Infect Dis. 2018 Apr;20(2):e12840. doi: 10.1111/tid.12840. Epub 2018 Feb 12.

Authors

Matias Chiarastelli Salomão¹, Marjorie Vieira Batista¹, Maria Cristina de Macedo², Mirian Nacagami Sotto³, Amaro Nunes Duarte⁴, Vanderson Geraldo Rocha², Hermes Ryoiti Higashino¹, Silvia Figueiredo Costa¹

Affiliations

¹ Department of Infectious Diseases, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
² Division of Hematology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
³ Department of Dermatology/Pathology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.
⁴ Department of Pathology, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil.

PMID: 29359841
DOI: 10.1111/tid.12840

Abstract

A patient with non-Hodgkin lymphoma, preparing for an autologous hematopoietic stem cell transplant (HSCT), developed leprosy. The patient was successfully treated with rifampicin, ofloxacin, and doxycycline, and the HSCT was performed without complications, being the first report, to our knowledge, of leprosy in an autologous HSCT patient.

Keywords: hematopoietic stem cell transplant; immunocompromised host; leprosy.

Publication types

Case Reports

MeSH terms

Adult
Anti-Bacterial Agents / therapeutic use
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Leprosy / complications*
Leprosy / drug therapy
Lymphoma, Non-Hodgkin / therapy*
Male

Substances

Anti-Bacterial Agents